27 June 2023 | Tuesday | News
GAVRETO was discovered by CStone's partner, Blueprint Medicines. CStone has an exclusive collaboration and license agreement with Blueprint Medicines for the development and commercialization of GAVRETO in Greater China, which encompasses Mainland China, Hong Kong, Macau and Taiwan.
GAVRETO was the first targeted RET inhibitor approved by China NMPA, and the therapy received initial approval in March 2021 for the treatment of locally advanced or metastatic RET fusion-positive NSCLC after platinum-based chemotherapy. It was also granted approval by the NMPA as the first selective RET inhibitor for the treatment of advanced RET-altered thyroid cancer in March 2022. Since being marketed in Greater China, GAVRETO is accessible in approximately 200 hospitals and DTP pharmacies and is covered by commercial insurance programs in 130 cities. GAVRETO has been included in various clinical guidelines and consensus based on its strong clinical profile.
Dr. Jason Yang, CEO of CStone, said, "We are delighted to see the approval of GAVRETO for the first-line treatment of RET-fusion positive NSCLC in China, broadening its indications to cover both first-line and second-line settings, as well as first-line RET-altered thyroid cancer. GAVRETO has treated thousands of patients since being marketed in China. As a biopharmaceutical company specialized in precision medicines and immunotherapies, CStone is committed to bringing more first-in-class and best-in-class therapies to patients worldwide."
Professor Yi-Long Wu of Guangdong Provincial People's Hospital, the Principal Investigator of the ARROW study in China, said, "Being the first RET inhibitor approved in China, GAVRETO has been proven to be an effective precision therapy. In the ARROW study, GAVRETO showed robust anti-tumor activity in Chinese patients with RET fusion-positive NSCLC regardless of prior treatments with a manageable safety profile and no new safety signals. This sNDA approval of GAVRETO is important to help improve clinical outcomes for Chinese RET fusion-positive NSCLC patients."
This sNDA approval is based on the results from the ARROW study, which is a global phase 1/2 clinical study designed to evaluate the safety, tolerability and efficacy of GAVRETO in patients with RET fusion-positive NSCLC, RET-mutant medullary thyroid cancer (MTC) and other advanced solid tumors with RET alterations.
Mostly recently in June, the updated efficacy and safety data from the ARROW study of GAVRETO in Chinese patients with RET fusion-positive NSCLC has been published on Cancer, a world-renowned oncology journal, which represents one additional recognition from the international academic community since the prior presentation at the 2022 European Society for Medical Oncology Asia Congress (ESMO Asia). The data showed that GAVRETO had robust and durable anti-tumor activity and a manageable safety profile in Chinese patients with locally advanced or metastatic RET fusion-positive NSCLC.
As of the data cut-off date (March 4, 2022), a total of 68 patients with advanced RET fusion-positive NSCLC were enrolled at 10 sites in China and received a starting GAVRETO dose of 400 mg once daily. Among these patients, 37 received prior platinum-based chemotherapy and 31 received no prior systemic treatment. Treatment response was assessed by Blinded Independent Central Review (BICR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
Efficacy: Durable and long-term clinical benefit of GAVRETO was observed in both treatment-naïve and previously treated Chinese patients with advanced RET fusion-positive NSCLC. The response rate in treatment-naïve patients was higher than the previously treated patient population.
Safety: GAVRETO had a generally manageable safety profile in Chinese patients, with no new safety signals observed.
 Zhou Q, et al. Efficacy and safety of pralsetinib in patients with advanced RET fusion-positive non–small cell lung cancer. Cancer. 2023 Jun 6. doi: 10.1002/cncr.34897.